Literature DB >> 15976109

Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma.

Edzard Schwedhelm1, Jing Tan-Andresen, Renke Maas, Ulrich Riederer, Friedrich Schulze, Rainer H Böger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15976109     DOI： 10.1373/clinchem.2004.046037

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  33 in total

1.  Simultaneous bioanalysis of L-arginine, L-citrulline, and dimethylarginines by LC-MS/MS.

Authors:  Soyoung Shin; Sun-Mi Fung; Srinidi Mohan; Ho-Leung Fung
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-01-14       Impact factor: 3.205

2.  Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.

Authors:  Bob Siegerink; Renke Maas; Carla Y Vossen; Edzard Schwedhelm; Wolfgang Koenig; Rainer Böger; Dietrich Rothenbacher; Hermann Brenner; Lutz P Breitling
Journal:  Clin Res Cardiol       Date:  2012-10-17       Impact factor: 5.460

3.  Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort.

Authors:  Nicole Lüneburg; Vanessa Xanthakis; Edzard Schwedhelm; Lisa M Sullivan; Renke Maas; Maike Anderssohn; Ulrich Riederer; Nicole L Glazer; Ramachandran S Vasan; Rainer H Böger
Journal:  J Nutr       Date:  2011-10-26       Impact factor: 4.798

4.  Asymmetric and Symmetric Dimethylarginines are Markers of Delayed Cerebral Ischemia and Neurological Outcome in Patients with Subarachnoid Hemorrhage.

Authors:  Daniel Appel; Miriam Seeberger; Edzard Schwedhelm; Patrick Czorlich; Alwin E Goetz; Rainer H Böger; Juliane Hannemann
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

5.  Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes.

Authors:  Sotoodeh Abhary; Kathryn P Burdon; Abraham Kuot; Shahrbanou Javadiyan; Malcolm J Whiting; Nicholas Kasmeridis; Nikolai Petrovsky; Jamie E Craig
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

6.  Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.

Authors:  Rainer H Böger; Lisa M Sullivan; Edzard Schwedhelm; Thomas J Wang; Renke Maas; Emelia J Benjamin; Friedrich Schulze; Vanessa Xanthakis; Ralf A Benndorf; Ramachandran S Vasan
Journal:  Circulation       Date:  2009-03-16       Impact factor: 29.690

7.  Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort.

Authors:  Renke Maas; Vanessa Xanthakis; Joseph F Polak; Edzard Schwedhelm; Lisa M Sullivan; Ralf Benndorf; Friedrich Schulze; Ramachandran S Vasan; Philip A Wolf; Rainer H Böger; Sudha Seshadri
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

8.  Asymmetric dimethylarginine and impaired cardiovascular healing.

Authors:  Giulio Coluzzi; Eleonora Santucci; Francesca Marzo; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2007-12-10       Impact factor: 2.300

9.  Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study.

Authors:  Aleksandra Pikula; Rainer H Böger; Alexa S Beiser; Renke Maas; Charles DeCarli; Edzard Schwedhelm; Jayandra J Himali; Friedrich Schulze; Rhoda Au; Margaret Kelly-Hayes; Carlos S Kase; Ramachandran S Vasan; Philip A Wolf; Sudha Seshadri
Journal:  Stroke       Date:  2009-07-30       Impact factor: 7.914

10.  Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines.

Authors:  Sotoodeh Abhary; Nicholas Kasmeridis; Kathryn P Burdon; Abraham Kuot; Malcolm J Whiting; Wai Ping Yew; Nikolai Petrovsky; Jamie E Craig
Journal:  Diabetes Care       Date:  2009-08-12       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.